Price Alert

Anika Therapeutics Inc. (ANIK)

NASDAQ: ANIK · Real-Time Price · USD

9.09

0.08 (0.89%)

At close: Sep 04, 2025, 11:52 AM

0.89% (1D)

Bid	9.02
Market Cap	131.02M
Revenue (ttm)	123.74M
Net Income (ttm)	-60.63M
EPS (ttm)	-0.9
PE Ratio (ttm)	-10.1
Forward PE	-22.32
Analyst	Buy

Ask	9.15
Volume	14,942
Avg. Volume (20D)	120,558
Open	9.03
Previous Close	9.01
Day's Range	9.03 - 9.19
52-Week Range	7.87 - 26.00
Beta	0.64

About ANIK

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANIK

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANIK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Anika Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-27.42%

Anika Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

3 months ago

-21.03%

Anika Therapeutics shares are trading lower after the company reported mixed Q1 financial results.

News

5 days ago · zacks.com

Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?

The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...

2 weeks ago · zacks.com

Anika (ANIK) Upgraded to Buy: Here's What You Should Know

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · seekingalpha.com

Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts

Anika Therapeutics is an HA-platform company with regenerative, OA pain, and non-orthopedic products. Their main line is called Integrity. But Hyalofast and Cingal can also eventually target the sizea...

1 month ago · seekingalpha.com

Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Cheryl Renee Blanchard - President, CEO & Director Matt Hall - Corporate Particip...

1 month ago · zacks.com

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.